在患有炎症性肠病的儿童和年轻成年患者中,乌斯特基努马布和维多利祖马布的实际疗效
在PubMed上查看摘要
概括
此摘要是机器生成的。在患有性结肠炎的儿科炎性肠病 (PIBD) 患者中,维多利祖马布的无类固醇缓解率高于乌斯特基努马布. 这两种生物药物在PIBD中都显示出安全性和有效性,但需要进行比较试验.
科学领域
- 儿童胃肠病学
- 免疫学
- 药理学
背景情况
- 乌斯特基努马布和维多利祖马布用于儿童炎症性肠病 (PIBD).
- 在PIBD管理中确定这些生物制剂的最佳使用和安全概况时,实际数据至关重要.
- 目前的证据需要对其在儿科患者群体中的比较有效性和安全性进行进一步调查.
研究的目的
- 在PIBD中评估ustekinumab和vedolizumab的6个月和1年的临床结果.
- 在现实环境中评估这些生物药物的治疗定位和安全性.
- 分析二次结果,包括内镜治疗和不良事件.
主要方法
- 对21岁以下被诊断患有IBD的患者进行回顾.
- 纳入标准:在2015年1月至2022年6月期间接受乌斯特基努马布或维多利祖马布治疗.
- 结果包括临床活性指数 (PUCAI,PPSC) 和便中calprotectin水平.
主要成果
- 与乌斯特基努马布相比,维多利祖马布在无类固醇治疗1年的临床缓解期显著更高 (61%对32%,p=0. 04).
- 这两种药物在克罗恩病患者的6个月和1年的临床缓解率相似.
- 大多数接受两种疗法的患者在6个月和1年内达到有利的calprotectin水平 (< 250μg/ g). 分别在6. 6%和10%的患者中报告了维多利祖马布和乌斯特基努马布的不良反应.
结论
- 在6个月和1年内实现PIBD临床缓解,乌斯特基努马布和维多利祖马布是安全有效的.
- 维多利祖马布在儿童性结肠炎中可能具有更高的疗效.
- 需要进行进一步的比较疗效临床试验,以确定这些生物制剂在PIBD中的确切作用.
相关概念视频
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

